0001701478
false
0001701478
2023-08-14
2023-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 14, 2023
AZITRA,
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41705 |
|
46-4478536 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
21
Business Park Drive
Branford,
CT 06405
|
(Address
of principal executive offices)(Zip Code) |
(203)
646-6446 |
(Registrant’s
telephone number, including area code) |
(Former
name or former address, if changed since last report.) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under
any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock: Par value $0.0001 |
|
AZTR |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
August 14, 2023, Azitra, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter
ended June 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The
information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 but shall
not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
Item
9.01 Financial Statements and Exhibits
(d) |
Exhibits |
Method
Filing |
The
following exhibit is furnished with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AZITRA,
INC. |
|
|
Dated:
August 14, 2023 |
/s/
Francisco D. Salva |
|
Francisco
D. Salva |
|
Chief
Executive Officer |
Exhibit 99.1
Azitra,
Inc. Announces Second Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn.,
August 14, 2023 - Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies
for precision dermatology, today reported financial results for the second quarter ended June 30, 2023.
Francisco Salva, Chief Executive Officer of Azitra,
commented, “We are extremely pleased with the exciting recent progress at Azitra, and we are thrilled to have closed on our initial
public offering in June. This year, we have demonstrated the potential of our regulatory, manufacturing, and clinical capabilities that
resulted in a new IND for ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Additionally, we are very pleased with the
recent progress of our platform and collaboration with Bayer.
Recent Business Highlights
|
● |
Completed an initial public offering: In June, the Company raised $7.5 million in gross proceeds in an initial public offering before deducting underwriting discounts and offering expenses. |
|
● |
Announced key appointments to executive team and board of directors: The Company made several key appointments during recent months, including Travis Whitfill as chief operating officer and Barbara Ryan and John Schroer to its board of directors. |
|
● |
Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome |
Financial Results for the Three Months Ended June 30, 2023
|
● |
Cash and cash equivalents: As of June 30, 2023, the Company had cash and cash equivalents of $6.3 million, which includes the proceeds from an initial public offering in June 2023. |
|
|
|
|
● |
Service Revenue – Related Party: The Company generated $172,000 of service revenue during the three months ended June 30, 2023 compared to service revenue of $85,000 for the comparable period in 2022. The increase of $87,000 in service revenue is attributable to an increase in the amount of reimbursable development costs incurred in 2023. |
|
|
|
|
● |
Research and Development
(R&D) expenses: R&D expenses for the three months ended June 30, 2023 were $812,836 compared to $1.5 million from the
prior year period. The decrease was primarily related to a decrease of $575,000 in research and development related costs attributable
to our efforts in moving our Netherton syndrome program forward and a net decrease in payroll and related costs of $120,000
attributable to a reduction in staff offset by a net increase in other costs of $2,389. There was no government and nonprofit grant
revenue received by us during the second quarter of fiscal 2023 or 2022. |
|
|
|
|
● |
General and Administrative (G&A) expenses: G&A expenses for the three months ended June 30, 2023 were $844,640 compared to $667,940 from the prior year period. The increase was primarily related to an increase of $259,000 in accounting, legal, hiring, and insurance costs offset by a decrease of $80,000 in payroll and related costs attributable to the discontinuation of separation benefits paid to our former chief operating officer, and $2,300 net decrease of other overhead expenses. |
|
|
|
|
● |
Net Loss was $4.4 million for the three months ended June 30 2023, compared to $1.9 million for the same period in 2022. |
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical
company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic
products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial
strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine
learning technology that analyzes, predicts and helps screen the Company’s library of strains for drug like molecules. The Company’s
initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company
considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit
https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such
as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,”
“seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking
statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking
statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation
of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04,
the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical
programs, and corporate and clinical/pre-clinical strategies.
Any forward-looking statements in this press release
are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks
and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial
for ATR-12 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates
may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation
of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient
competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property
crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not
be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing,
research and preclinical and clinical testing. Additional risks concerning Azitra’s programs and operations are described in its
registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with
the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Company Contact
Norman Staskey
Chief Financial Officer
staskey@azitra.com
Condensed Consolidated Statement of Operations
(Unaudited)
|
|
Three months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
Service revenue – related party |
|
$ |
172,000 |
|
|
$ |
85,000 |
|
Total revenue |
|
|
172,000 |
|
|
|
85,000 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
General and administrative |
|
|
844,640 |
|
|
|
667,940 |
|
Research and development |
|
|
812,836 |
|
|
|
1,505,447 |
|
Total operating expenses |
|
|
1,657,476 |
|
|
|
2,173,387 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(1,485,476 |
) |
|
|
(2,088,387 |
) |
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income |
|
|
265 |
|
|
|
335 |
|
Interest expense |
|
|
(76,187 |
) |
|
|
(17,811 |
) |
Employee retention credit |
|
|
- |
|
|
|
229,813 |
|
Other income |
|
|
1,600 |
|
|
|
- |
|
Forgiveness of accounts payable |
|
|
56,285 |
|
|
|
- |
|
Change in fair value of convertible note |
|
|
(2,830,100 |
) |
|
|
- |
|
Other expense |
|
|
(95,915 |
) |
|
|
(14,103 |
) |
Total other income (expense) |
|
|
(2,944,052 |
) |
|
|
198,234 |
|
|
|
|
|
|
|
|
|
|
Net loss before income taxes |
|
|
(4,429,528 |
) |
|
|
(1,890,153 |
) |
|
|
|
|
|
|
|
|
|
Income tax benefit (expense) |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,429,528 |
) |
|
|
(1,890,153 |
) |
Dividends on preferred stock |
|
|
(643,267 |
) |
|
|
(692,246 |
) |
Net loss attributable to common shareholders |
|
$ |
(5,072,795 |
) |
|
|
(2,582,399 |
) |
Net loss per Share, basic and diluted |
|
|
(2.36 |
) |
|
|
(2.45 |
) |
Weighted average common stock outstanding, basic and diluted |
|
$ |
2,147,526 |
|
|
$ |
1,055,454 |
|
Condensed Consolidated Balance Sheets
(Unaudited)
|
|
June 30, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
6,290,355 |
|
|
$ |
3,492,656 |
|
Other receivables |
|
|
501,288 |
|
|
|
266,208 |
|
Prepaid expenses and other current assets |
|
|
48,523 |
|
|
|
377,019 |
|
Total current assets |
|
$ |
6,840,166 |
|
|
$ |
4,135,883 |
|
Property and equipment, net |
|
|
803,107 |
|
|
|
846,958 |
|
Other assets |
|
|
2,186,284 |
|
|
|
2,184,602 |
|
Total assets |
|
$ |
9,829,557 |
|
|
$ |
7,167,443 |
|
Liabilities, preferred stock, and stockholders’ equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
364,183 |
|
|
$ |
784,687 |
|
Current operating lease liability |
|
|
298,047 |
|
|
|
287,384 |
|
Accrued expenses |
|
|
767,721 |
|
|
|
993,961 |
|
Contract liabilities |
|
|
310,700 |
|
|
|
156,000 |
|
Total current liabilities |
|
|
1,740,651 |
|
|
|
2,222,032 |
|
Long-term operating lease liability |
|
|
693,609 |
|
|
|
840,896 |
|
Warrant liability |
|
|
158,994 |
|
|
|
70,283 |
|
Convertible notes payable, net |
|
|
0 |
|
|
|
6,600,000 |
|
Total liabilities |
|
|
2,593,254 |
|
|
|
9,733,211 |
|
Stockholders’ equity (deficit) |
|
|
|
|
|
|
|
|
Preferred stock |
|
|
0 |
|
|
|
33,694,542 |
|
Common stock |
|
|
1,210 |
|
|
|
104 |
|
Additional paid-in capital |
|
|
51,436,352 |
|
|
|
1,054,138 |
|
Accumulated deficit |
|
|
(44,201,259 |
) |
|
|
(37,314,552 |
) |
Total stockholders’ equity (deficit) |
|
|
7,236,303 |
|
|
|
(36,260,310 |
) |
Total liabilities, preferred stock and stockholders’ equity (deficit) |
|
$ |
9,829,557 |
|
|
$ |
7,167,443 |
|
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Azitra (AMEX:AZTR)
Historical Stock Chart
From May 2024 to Jun 2024
Azitra (AMEX:AZTR)
Historical Stock Chart
From Jun 2023 to Jun 2024